News | May 22, 2024
AstraZeneca plans $1.5 billion ADCs manufacturing facility in Singapore
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The proposed facility is expected to be operational around January, 2027
Subscribe To Our Newsletter & Stay Updated
